Carcinoma of the prostate: pathology, staging, and treatment (Q39566920)

13 September 2017

1 reference

title

Carcinoma of the prostate: pathology, staging, and treatment (English)

1 reference

13 September 2017

Freiha FS

1

1 reference

13 September 2017

Bagshaw MA

series ordinal

2

1 reference

13 September 2017

Torti FM

series ordinal

3

1 reference

13 September 2017

publication date

1 November 1988

1 reference

Current Problems in Cancer

13 September 2017

published in

1 reference

13 September 2017

volume

12

1 reference

13 September 2017

issue

6

1 reference

13 September 2017

page(s)

329-411

1 reference

Patterns of progression in prostate cancer

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Hormone therapy in prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

T.N.M. classification for urological tumours (U.I.C.C.) - 1974

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Ultrasonography of prostatic carcinoma employing amplitude-enveloped (AM) and frequency-demodulated (FM) imaging: in vivo, in vitro, and pathologic correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Prostatic evaluation by transrectal sonography with histopathologic correlation: the echopenic appearance of early carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Prostatic carcinoma: detection and staging using suprapubic US.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Preoperative evaluation of localized prostatic carcinoma by transrectal ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Computed tomography in the evaluation, staging, and therapy of carcinoma of the bladder and prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

The value of computerized tomography scan and magnetic resonance imaging in staging prostatic carcinoma: comparison with the clinical and histological staging.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Surgical staging of prostatic cancer: transperitoneal versus extraperitoneal lymphadenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Pelvic Lymphadenectomy for Staging Prostatic Carcinoma: Is it Always Necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Efficacy of radical prostatectomy for stage A2 carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Operable prostatic carcinoma: correlations among clinical stage, pathological stage, gleason histological score and early disease-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Surgical treatment of stage A2 prostatic carcinoma: significance of tumor grade and extent

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Radical Surgery for Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Total prostatectomy for localized prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Radical retropubic prostatectomy after transurethral prostatic resection

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

The morbidity of radical prostatectomy for multifocal stage I prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Carcinoma of the Prostate: A Study of 213 Patients with Stage C Tumors Treated by Total Perineal Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

A study of 229 consecutive cases of total perineal prostatectomy for cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

External beam radiation salvage for residual or recurrent local tumor following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Impotence following radical prostatectomy: insight into etiology and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

The role of radical prostatectomy in the management of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

A comparison of the morbidity associated with radical retropubic prostatectomy with and without pubectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Definitive radiation therapy of carcinoma of the prostate. A report on 15 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Selecting initial therapy for prostate cancer. Radiation therapy perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Current conflicts in the management of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Tumor control in definitive irradiation of localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate--analysis of RTOG study 75-06

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Results of treatment with radiotherapy in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment of carcinoma of the prostate by interstitial radiation with radio-active gold (Au 198): a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

AN ASSESSMENT OF THE VALUE OF RADIOTHERAPY IN THE MANAGEMENT OF CARCINOMA OF THE PROSTATE

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Fast neutron radiotherapy for locally advanced prostate cancer: results of an RTOG randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Extended field (periaortic) irradiation in carcinoma of the prostate--analysis of RTOG 75-06

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Prognostic factors in carcinoma of the prostate--analysis of RTOG study 75-06

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Local hyperthermia for treatment of carcinoma of the prostate: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Radical perineal prostatectomy for palpable, clinically localized, non-obstructive cancer: experience at the Johns Hopkins Hospital 1909-1963

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Serum phosphatase determinations in diagnosis of prostatic cancer; a review of 1,150 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Carcinoma of the prostate: treatment comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Proceedings: The natural history of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Orchiectomy for advanced prostatic carcinoma A reevaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment options for patients with stage D1 (T0-3,N1-2,M0) adenocarcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Endocrine changes after diethylstilbestrol therapy Effects on prostatic neoplasm and pituitary-gonadal axis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Intermittent endocrine therapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Regression of prostatic cancer metastasis by high doses of diethylstilbestrol diphosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

TACE in prostatic cancer: clinical and biochemical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment of Advanced Prostatic Carcinoma with Estracyt: A Preliminary Report

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment of Advanced Carcinoma of the Prostate with Estramustine Phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment of advanced carcinoma of the prostate with estramustine phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment of Rapidly Progressing Prostatic Carcinoma with Estracyt

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Extended Therapy of Stage D Carcinoma of the Prostate with Oral Estramustine Phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

The Treatment of Oestrogen-Escaped Carcionoma of the Prostate with Estramustine Phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

The biology of gonadotropin-releasing hormone and its analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Intranasal buserelin in the treatment of advanced prostatic cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Hypophysectomy in the treatment of disseminated prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Aminoglutethimide therapy for advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment of advanced prostatic cancer, resistant to conventional therapy, with aminoglutethimide

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

High-dose ketoconazole therapy in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Antiandrogenic Effects of Spironolactone: Hormonal and Ultrastructural Studies in Dogs and Men

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Effect of cyproterone acetate on clinical, endocrine and pathological features of benign prostatic hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Cyproterone Acetate in the Treatment of Advanced Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Experience in the Treatment of Prostatic Carcinoma with Cyproterone Acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

A Morphological Study on the Effect of Cyproterone Acetate on Human Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Advanced prostatic carcinoma Flutamide therapy after conventional endocrine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

SCH 13521 in the treatment of advanced carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Megestrol acetate for treatment of advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment of advanced cancer of prostate with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Clinical significance of the human acid phosphatases: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Comparison of total and prostatic fraction serum acid phosphatase levels in patients with differentiated and undifferentiated prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Management of occult prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Prognostic usefulness of serum acid phosphatase levels in carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Acid phosphatase for monitoring prostatic carcinoma. Comparison of radioimmunoassay and enzymatic techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Dose response evaluation of adriamycin in human neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: Prognostic factors and response

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment of advanced carcinoma of the prostate (stage D) with infusion of cis-diamminedichloroplatinum (II NSC 119875): a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Chemotherapy of advanced, hormonally resistant prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Early combined hormonal and chemotherapy for metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Testosterone potentiated 32P therapy in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Proceedings: Testosterone potentiated radiophosphorus therapy of osseous metastases in prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Phosphorus-32 for intractable pain in carcinoma of prostate. Analysis of androgen priming, parathormone rebound, and combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Radioactive phosphorus in the treatment of metastasis to bone from carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2888%2980003-5

7 January 2021

10.1016/S0147-0272(88)80003-5

Identifiers

DOI

1 reference

13 September 2017

1 reference